学会及びパブリケーション

Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting

Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting

Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305

Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305

Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Zanubrutinib vs. acalabrutinib in B-cell malignancies: an adverse event-based economic analysis

Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis Efficacy and safety of zanubrutinib vs. venetoclax+ibrutinib in the treatment-naïve (TN) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory follicular lymphoma using the growth modulation index Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus real-world chemoimmunotherapy (CIT) or chemotherapy (Chemo) in relapsed/refractory marginal zone lymphoma (R/R MZL) Patient-reported outcome (PRO)–based recurrent symptomatic deterioration predicts disease progression: results from the ALPINE trial Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Real-world evaluation of treatment patern, time to next treatment, healthcare resource utilization, and cost of care in follicular lymphoma Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia patients treated with Bruton tyrosine kinase inhibitors: a real-world study using the Symphony Health Solutions database Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström's macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14) Zanubrutinib vs other Bruton’s tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia: a multilevel network meta-regression

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive (TN) CLL Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis Efficacy and safety of zanubrutinib vs. venetoclax+ibrutinib in the treatment-naïve (TN) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory follicular lymphoma using the growth modulation index Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus real-world chemoimmunotherapy (CIT) or chemotherapy (Chemo) in relapsed/refractory marginal zone lymphoma (R/R MZL) Patient-reported outcome (PRO)–based recurrent symptomatic deterioration predicts disease progression: results from the ALPINE trial Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Real-world evaluation of treatment patern, time to next treatment, healthcare resource utilization, and cost of care in follicular lymphoma Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL Recent patterns of care with btk inhibitors and distribution of social determinants of health among patients with cll/sll in the us community setting Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia patients treated with Bruton tyrosine kinase inhibitors: a real-world study using the Symphony Health Solutions database Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström's macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14) Zanubrutinib vs other Bruton’s tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia: a multilevel network meta-regression Zanubrutinib vs. acalabrutinib in B-cell malignancies: an adverse event-based economic analysis

A first in human phase 1a dose escalation study of BGB 15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti PD 1 antibody) in patients (pts) with advanced solid tumors BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia BGB-A317-212: a multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis (NMA) Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: an open-label, single-arm, multicenter phase II study Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL) Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: results from RATIONALE 305

A first in human phase 1a dose escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti PD 1 antibody) in patients (pts) with advanced solid tumors BGB-11417-203: an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia BGB-A317-212: a multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis (NMA) Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based analysis Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL) Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL) Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia (CLL) patients (pts) treated with Bruton tyrosine kinase inhibitors (BTKis): a real-world data study using the Symphony Health Solutions database Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: results from RATIONALE 305

Budget impact analysis of zanubrutinib + obinutuzumab for the treatment of relapsed or refractory follicular lymphoma in the United States Clinical outcomes of first-line (1L) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR) Clinical outcomes of second-line (2L) treatments (txs) in locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a systematic literature review (SLR) Clinical outcomes of second-line and beyond (2L+) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR) Outcomes with novel therapies for relapsed or refractory follicular lymphoma: a targeted literature review Systematic literature review (SLR) of randomized controlled trials (RCTs) of immuno-oncology (IO) for first-line (1L) esophageal squamous cell carcinoma (ESCC) in adults patients Systematic literature review (SLR) of randomized controlled trials (RCTs) of immuno-oncology (IO) for first-line (1L) esophageal squamous cell carcinoma (ESCC) in adults patients (Supplemental) Targeted literature review of cost-effectiveness models in relapsed/refractory follicular lymphoma

Budget impact analysis of zanubrutinib + obinutuzumab for the treatment of relapsed or refractory follicular lymphoma in the United States Clinical outcomes of first-line (1L) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR) Clinical outcomes of second-line (2L) treatments (txs) in locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a systematic literature review (SLR) Clinical outcomes of second-line and beyond (2L+) treatments (txs) in locally advanced or metastatic non-small cell lung cancer (aNSCLC): a systematic literature review (SLR) Outcomes with novel therapies for relapsed or refractory follicular lymphoma: a targeted literature review Systematic literature review (SLR) of randomized controlled trials (RCTs) of immuno-oncology (IO) for first-line (1L) esophageal squamous cell carcinoma (ESCC) in adults patients Targeted literature review of cost-effectiveness models in relapsed/refractory follicular lymphoma

Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: an ongoing phase 1/2 study

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia that progressed in the ALPINE study First results from a phase 1, first-in-human study BGB-16673 in patients with relapsed/refractory B-cell malignancies Ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory marginal zone lymphoma: an ongoing phase 1 study Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia that progressed in the ALPINE study Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL First results from a phase 1, first-in-human study BGB-16673 in patients with relapsed/refractory B-cell malignancies Ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: an ongoing phase 1/2 study Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory marginal zone lymphoma: an ongoing phase 1 study Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison